

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 20845

MEDICAL REVIEW(S)

MedDune
OCT 29 1999

**Primary Medical Review
of Inhaled Nitric Oxide (I-NO)**

NDA 20-845

**Food and Drug Administration
Division of Cardio-Renal Drug Products (HFD-110)**

October 29, 1999

**By
Douglas C. Throckmorton, M.D.**

Table of Contents

	Page #
General Information	1-4
0.0 Overall Summary	4-5
1.0 Materials Used for Review	5
2.0 Background	5-6
3.0 Review of CINRGI	7-23
3.1 Title of Study	7
3.2 Sites of Investigation and Investigators/Financial Disclosure	7
3.3 Background	7
3.4 Study Design	8-9
3.5 Primary And Secondary Objective/Endpoints	9
3.6 Number Of Subjects/ Randomization	9
3.7 Inclusion/ Exclusion Criteria	9-10
3.8 Dosage/ Administration	10
3.9 Duration/ Adjustment of Therapy	10
3.10 Safety and Efficacy Endpoint Measured	10
3.11 Statistical Considerations	10-11
3.12 Efficacy Outcomes	11-20
3.12.1 Patient Demographics and Baseline Characteristics	11-14
3.12.2 Disposition and Follow-up for Subjects	14
3.12.2a Subject Selection	14
3.12.2b Protocol Violations and Deviations	14
3.12.2c Patient Randomization & Completion	15
3.12.2c Concomitant Therapies Used After Trial Initiation	15
3.12.3 Analysis of Primary Endpoint	16
3.12.4 Analysis of Secondary Endpoints from CINRGI	16-18
3.12.5 Additional Analyses of CINRGI	19-20
3.13 Safety Outcomes	21-23
3.13.1 Deaths in CINRGI	21
3.13.2 Serious Adverse Events in CINRGI	21
3.13.3 Adverse Events in CINRGI	21-22
3.13.4 Discontinuations in CINRGI	23
3.13.5 Lab Adverse Events and Special Studies	23
3.14 Efficacy Summary For CINRGI	24-28
3.15 Safety Summary For CINRGI	29
3.16 Overall Summary for CINRGI	30
4.0 Long-Term Follow-Up for INO-01/ -02 and NINOS	31-46
4.1 NINOS Follow-Up	31-41
4.1.1 Additional NINOS Analyses: Receipt of ECMO	32-37
4.1.2 NINOS Follow-Up Results	38-41
4.2 INO-01/ -02 Follow-Up	42-46
5.0 Integrated Efficacy Summary from NDA Trials	47-66
5.1 Demographics	47-52
5.1.1 Population Demographics	47-48
5.1.2 Clinical Demographics	58-52
5.2 Extent of exposure (dose/duration)	53
5.3 Primary and secondary efficacy endpoints	53-54
5.4 Success of trials in meeting pre-specified primary endpoints	55-56
5.4.1 Sub-Group Analyses of the Primary Endpoint	56-59
5.5 Success of trials in meeting secondary efficacy endpoints: demonstrating a physiological effect of I-NO	59-63
5.6 Success of trials in meeting secondary efficacy endpoints: demonstrating a clinical benefit for I-NO	64-66
5.7 Clinical effect of I-NO from the secondary data sources	66

Table of Contents (cont)

	Page #
6.0 Integrated Safety Summary from NDA Trials	67-83
6.1. General Comments about Adverse Event collection	67
6.2 Acute pulmonary injury	67-69
6.3 Chronic Pulmonary Injury	70-71
6.6. Acute Neurological Injury	72
6.5 Chronic Neurological Injury	73-74
6.6 Laboratory Abnormalities	75
Increased Methemoglobin and NO ₂ concentrations	75-77
Eosinophilia	78-79
Abnormal LFTs	79-82
6.7 Other Laboratory Measurements	82
6.8. Miscellaneous Adverse Events	83
7.0 Overall Summary of Efficacy and Safety for I-NO	84-86
8.0 References	86
<u>Appendices</u>	
9.0 Appendix One: Abbreviations Used	87
10.0 Appendix Two: Death Narratives from the CINRGI Trial	88-91
11.0 Appendix Three: Patient Disposition in the CINRGI Trial	92
12.0 Appendix Four: Proposed Label	93-104

NDA: 20-845

NAME OF DRUG: Inhaled Nitric Oxide (I-NO)

TRADE NAME: INOmax

FORMULATION: Gas for inhalation

RELATED APPLICATION: None

DATE OF SUBMISSION: 5.25.99

DATE RECEIVED BY FDA: 5.26.99

DATE ASSIGNED TO CURRENT REVIEWER: 6.17.97(see below)

DATE REVIEW COMPLETED: 10.29.99

PROPOSED INDICATION: Treatment of hypoxic respiratory failure in newborns

SPONSOR/MONITORS: INO Therapeutics, Inc.

/s/

H.O.

Douglas C. Throckmorton, M.D.
Primary Medical Reviewer

0.0 Overall Summary of Efficacy and Safety for I-NO

Inhaled Nitric Oxide (I-NO) has been proposed as a treatment for hypoxic respiratory failure in neonates. Clinical support for this indication comes from four clinical trials conducted in this population and submitted as part of this NDA, as well as an extensive published literature on the use of I-NO in this setting. Three of these trials were previously reviewed as part of an earlier NDA submission by the sponsor. The fourth trial was completed more recently and is reviewed as part of the present document.

The data from three trials (NINOS, INO-01/ -02 and CINRGI) demonstrate that I-NO administration is associated with a significant decrease in the use of extra-corporeal membrane oxygenation (ECMO), an invasive method of oxygenating the blood. This effect of I-NO to decrease ECMO use may well be due to the acute effect of I-NO to improve oxygenation, rather than due to any other beneficial effect on the course of the disease causing the hypoxic respiratory failure. In support of this contention, no beneficial effect of I-NO on mortality or any other clinical endpoint was demonstrated by the available data. No effect of I-NO on mortality (beneficial or adverse) has been demonstrated by the data. The effect of I-NO to improve oxygenation is significant, however, and avoidance of ECMO is a clinically-desirable outcome. In the absence of hard clinical benefit (e.g., decreased mortality, fewer days of hospitalization) the safety of I-NO needs to be firmly established prior to allowing its non-investigational use.

The following safety issues have been raised during one or both of my reviews:

1) The safety database included small number of subjects, and for most adverse events, the INO-01/ -02 was the primary source of information. Given the baseline differences between the subjects in the INO-01/ -02 and the other trials, extrapolating between the two populations is also difficult, and open to serious errors of omission due to inadequate data. These difficulties have been alleviated to some extent by the addition of 97 additional patients who were exposed to I-NO, bringing the total number of children exposed to I-NO in the NDA database to 375. The difficulties with differences in baseline characteristics are again present in the CINRGI trial, complicating its interpretation. Another potentially confounding variable between the CINRGI trial and the previous trials is the lower dose of I-NO administered in CINRGI (20 ppm reduced to 5 ppm if possible), compared with the NINOS and INO-01/ -02 trials (20-80 ppm).

2) The available safety database in the original NDA raised several potential safety issues. The most troubling of the adverse events, raised in the original medical review, was the possible association of I-NO with acute and chronic pulmonary toxicities. This association, like all of the safety data, relied on small numbers of subjects, although the association was plausible, given the available data. The addition of the CINRGI trial data, along with additional long-term follow-up data from NINOS and INO-01/ -02 has allayed some of the concerns, especially regarding the occurrence of chronic injury. The existing database is inadequate, however, to exclude the occurrence of pulmonary toxicity in association with the use of I-NO.

3) There was a definite association of I-NO with the development of methemoglobinemia and elevated NO₂ concentrations, identified in the NINOS and INO-01/ -02 trials (especially at the 80 ppm dose). This concern is minimized with the use of the lower doses of I-NO in the CINRGI trial (and the proposed dose for the label).

4) Several other adverse events were also possibly linked to the administration of I-NO based on the data available in 1997, although the data were insufficient to determine the seriousness of these potential adverse events, or to determine their duration or dose-response. The addition of the CINRGI data has resolved some of these safety concerns, and no new safety concerns have arisen as a result of the CINRGI trial review. The available data does suggest that rapid discontinuation of I-NO is associated with rebound hypoxia in some patients.

5) For some adverse events of interest, no data were obtained at all. Most critical of these was the effect of I-NO on coagulation parameters. Other clinical events for which we have either scarce or no clinical data include: musculoskeletal injury; non-glomerular renal injury; effects on the cardiac conduction system, and effects on serum electrolytes.

6) The number of patients exposed to I-NO is too small to adequately assess the potential interactions of I-NO with disease states, patient demographics and concomitant medications. The potential interaction of I-NO with other drugs is of particular importance for drugs commonly used to treat this condition, such as steroids and vasodilators (with the exception of tolazoline).

7) Finally, an issue that cannot be resolved from the database is the potential genotoxicity and carcinogenicity of I-NO. The available data on the genotoxicity of I-NO are mixed (see section 4.1 in my 1997 review for details). It is true that the duration of exposure to I-NO is limited in these studies, and that I-NO is produced (at many-fold lower concentrations) intracellularly. However, the cumulative years of risk for a newborn who receives I-NO is appreciably longer than an adult.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.